Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 6 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves Outcomes in Pretreated Patients with Metastatic Cancer ESMO 2025: A Glimpse Into the Congress Programme, Berlin, Germany, 17-21 October ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 MOST POPULAR Community Surprises Teen Battling Bone Cancer With Brand New Car For... January 26, 2022 EMA Recommends Extension of Indications for Durvalumab to Include Treatment of... March 28, 2025 FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma April 27, 2022 EMA Recommends Extension of Indications for Crizotinib September 23, 2022 Load more HOT NEWS TRACERx EVO, a new programme to transform lung cancer research Cell Therapy Improves Progression-Free Survival in Advanced Melanoma, First Phase 3... Should People With Cancer Be Tested for Hepatitis B? ASCO 2023 roundup: Blood tests, drugs and exercise
